| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |